Pauline Funchain
@funchainmd.bsky.social
Melanoma oncology @Stanford. Study hereditary genetics and irAEs. LA explant in SF via Ohio State, NIH/NHGRI, Harbor UCLA, and Cleveland Clinic. Sports fan, geek and mom. APD Hem/Onc fellowship. ASPirE founder, Checkpoint Now. COI http://bit.ly/43UCDOz
Is this explosive growth in publications good for science: Fabulous questions posed and thoughtful summary on the state of publications today by @kbibbinsdomingo.bsky.social editor in chief @jama.com
Medicine Grand Rounds @stanfordmedicine.bsky.social
Medicine Grand Rounds @stanfordmedicine.bsky.social
November 5, 2025 at 8:22 PM
Is this explosive growth in publications good for science: Fabulous questions posed and thoughtful summary on the state of publications today by @kbibbinsdomingo.bsky.social editor in chief @jama.com
Medicine Grand Rounds @stanfordmedicine.bsky.social
Medicine Grand Rounds @stanfordmedicine.bsky.social
🚨 irAE aficionados! This Friday! @aspire-cop.bsky.social is at @sitcancer.bsky.social 🥳
⏱️4-6p
📍Chesapeake Rm 2-3
More details below:
⏱️4-6p
📍Chesapeake Rm 2-3
More details below:
November 5, 2025 at 1:49 AM
🚨 irAE aficionados! This Friday! @aspire-cop.bsky.social is at @sitcancer.bsky.social 🥳
⏱️4-6p
📍Chesapeake Rm 2-3
More details below:
⏱️4-6p
📍Chesapeake Rm 2-3
More details below:
AI in Clinical Science - amazing data being presented today by @jason-fries.bsky.social Sylvia Plevritis @roxanadaneshjou.bsky.social @akshay-chaudhari.bsky.social but still feel like we are just barely cracking the egg in this field. So impatient for the omelette…!
@stanford-cancer.bsky.social
@stanford-cancer.bsky.social
November 4, 2025 at 10:33 PM
AI in Clinical Science - amazing data being presented today by @jason-fries.bsky.social Sylvia Plevritis @roxanadaneshjou.bsky.social @akshay-chaudhari.bsky.social but still feel like we are just barely cracking the egg in this field. So impatient for the omelette…!
@stanford-cancer.bsky.social
@stanford-cancer.bsky.social
Ever wonder why our HLA specified cancer therapies are only for HLA02:01 thus far? @possuhuanglab.bsky.social presents the scope of the problem at the inaugural @stanford-cancer.bsky.social AI and Cancer Research Symposium 🧬
November 4, 2025 at 6:12 PM
Ever wonder why our HLA specified cancer therapies are only for HLA02:01 thus far? @possuhuanglab.bsky.social presents the scope of the problem at the inaugural @stanford-cancer.bsky.social AI and Cancer Research Symposium 🧬
Seeing the future: from Election Day straight to AI and Cancer Research @stanford-cancer.bsky.social
Keynote speaker Michelle Mello @law.stanford.edu with involved Q&A over the use of AI in prior auth
Keynote speaker Michelle Mello @law.stanford.edu with involved Q&A over the use of AI in prior auth
November 4, 2025 at 5:31 PM
Seeing the future: from Election Day straight to AI and Cancer Research @stanford-cancer.bsky.social
Keynote speaker Michelle Mello @law.stanford.edu with involved Q&A over the use of AI in prior auth
Keynote speaker Michelle Mello @law.stanford.edu with involved Q&A over the use of AI in prior auth
“A child does not pay for his mother’s milk.” 🙏
Profound global cancer lessons from Dr. Miriam Mutebi
Nothing like #ESMO25 back-to-back with a deep dive into cancer in Africa to understand cancer as a truly 🌍 global effort
@stanfordmedicine.bsky.social Grand Rounds 👏
@stanford-cancer.bsky.social
Profound global cancer lessons from Dr. Miriam Mutebi
Nothing like #ESMO25 back-to-back with a deep dive into cancer in Africa to understand cancer as a truly 🌍 global effort
@stanfordmedicine.bsky.social Grand Rounds 👏
@stanford-cancer.bsky.social
October 22, 2025 at 7:42 PM
“A child does not pay for his mother’s milk.” 🙏
Profound global cancer lessons from Dr. Miriam Mutebi
Nothing like #ESMO25 back-to-back with a deep dive into cancer in Africa to understand cancer as a truly 🌍 global effort
@stanfordmedicine.bsky.social Grand Rounds 👏
@stanford-cancer.bsky.social
Profound global cancer lessons from Dr. Miriam Mutebi
Nothing like #ESMO25 back-to-back with a deep dive into cancer in Africa to understand cancer as a truly 🌍 global effort
@stanfordmedicine.bsky.social Grand Rounds 👏
@stanford-cancer.bsky.social
Pledge allegiance to your hands, your team, your vibes/all the airports you have been/Caffeine, you’re mine/ it’s ‘bout to be the sleepless night/ because of ESMO #yayjetlag #LifeofanAcademicGirl
October 16, 2025 at 8:03 PM
Pledge allegiance to your hands, your team, your vibes/all the airports you have been/Caffeine, you’re mine/ it’s ‘bout to be the sleepless night/ because of ESMO #yayjetlag #LifeofanAcademicGirl
The Mount Rushmore of @stanford-cancer.bsky.social leaders past and present at a fireside chat, reflecting on their career paths, their pivotal choices, how they maintain high achievement with non-academic life #Asilomar25
October 9, 2025 at 6:38 PM
The Mount Rushmore of @stanford-cancer.bsky.social leaders past and present at a fireside chat, reflecting on their career paths, their pivotal choices, how they maintain high achievement with non-academic life #Asilomar25
Fangirling here - Sumbul Desai VP of Health at Apple, previously worked at Disney, now bringing access to health information to the masses with a small metal and glass box that sits on your wrist #MGR @stanforddeptmed.bsky.social
September 17, 2025 at 7:52 PM
Fangirling here - Sumbul Desai VP of Health at Apple, previously worked at Disney, now bringing access to health information to the masses with a small metal and glass box that sits on your wrist #MGR @stanforddeptmed.bsky.social
#CCRTP25 cancer immunotherapy session covering the breadth of anti tumor immunity - immune tolerance incited by lymph node involvement @retickerflynn.bsky.social, cytokine conditioning of T cells - A Kalbasi, and synthetic engineering of cytokine receptors - K Daniels @stanford-cancer.bsky.social
September 16, 2025 at 6:01 PM
#CCRTP25 cancer immunotherapy session covering the breadth of anti tumor immunity - immune tolerance incited by lymph node involvement @retickerflynn.bsky.social, cytokine conditioning of T cells - A Kalbasi, and synthetic engineering of cytokine receptors - K Daniels @stanford-cancer.bsky.social
Good morning Redwood City 🌞 Rise and shine to Day 2 of the #CCRTP25 @stanford-cancer.bsky.social Still unbelievable to be colleagues with Dr Ron Levy and see how integrated and committed he is to educating the next generation of cancer researchers
September 16, 2025 at 4:14 PM
Good morning Redwood City 🌞 Rise and shine to Day 2 of the #CCRTP25 @stanford-cancer.bsky.social Still unbelievable to be colleagues with Dr Ron Levy and see how integrated and committed he is to educating the next generation of cancer researchers
Great 💎s on GI cancers at #CCRTP25 @stanford-cancer.bsky.social @corsello.bsky.social
-drug discovery w better yield from unexpected hits, then subsequently modified
-negative results so important to publish
-environmental factors like weight most likely culprits of young onset colon cancer
-drug discovery w better yield from unexpected hits, then subsequently modified
-negative results so important to publish
-environmental factors like weight most likely culprits of young onset colon cancer
September 15, 2025 at 6:47 PM
Great 💎s on GI cancers at #CCRTP25 @stanford-cancer.bsky.social @corsello.bsky.social
-drug discovery w better yield from unexpected hits, then subsequently modified
-negative results so important to publish
-environmental factors like weight most likely culprits of young onset colon cancer
-drug discovery w better yield from unexpected hits, then subsequently modified
-negative results so important to publish
-environmental factors like weight most likely culprits of young onset colon cancer
So far we have talked about non smoking Asian females (lung cancer) and people in their 30s and 40s (colon cancer) and I’m feeling a bit targeted in the worst way 😂 #CCRTP25 @stanford-cancer.bsky.social
September 15, 2025 at 6:09 PM
So far we have talked about non smoking Asian females (lung cancer) and people in their 30s and 40s (colon cancer) and I’m feeling a bit targeted in the worst way 😂 #CCRTP25 @stanford-cancer.bsky.social
The amazing breath of nicotine products today, with significantly higher amounts of nicotine than cigarettes, covered by keynote speaker Carly Kajiwara from the Halpern-Felsher Lab @stanford-cancer.bsky.social #CCRTP25
September 15, 2025 at 4:30 PM
The amazing breath of nicotine products today, with significantly higher amounts of nicotine than cigarettes, covered by keynote speaker Carly Kajiwara from the Halpern-Felsher Lab @stanford-cancer.bsky.social #CCRTP25
Good morning Redwood City 🌞 Rise and shine for an action packed day at the Comprehensive Cancer Research Training Program @stanford-cancer.bsky.social - Day 1 of 2 for soaking in cancer research 🤓🥳
September 15, 2025 at 3:14 PM
Good morning Redwood City 🌞 Rise and shine for an action packed day at the Comprehensive Cancer Research Training Program @stanford-cancer.bsky.social - Day 1 of 2 for soaking in cancer research 🤓🥳
Melanoma orals #8 ➡️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets
➡️First randomized trial in symptomatic brain mets
➡️Significant PFS improvement with triple therapy over ipi nivo
➡️No significant OS benefit
Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social
➡️First randomized trial in symptomatic brain mets
➡️Significant PFS improvement with triple therapy over ipi nivo
➡️No significant OS benefit
Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social
June 3, 2025 at 5:11 PM
Melanoma orals #8 ➡️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets
➡️First randomized trial in symptomatic brain mets
➡️Significant PFS improvement with triple therapy over ipi nivo
➡️No significant OS benefit
Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social
➡️First randomized trial in symptomatic brain mets
➡️Significant PFS improvement with triple therapy over ipi nivo
➡️No significant OS benefit
Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social
Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
June 3, 2025 at 5:03 PM
Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
June 3, 2025 at 5:02 PM
Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
➡️ 63.3% for ipi/nivo first
➡️ 33.9% for dab/tram first
Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social
Melanoma orals #6 ➡️ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma
pCR 71% MPR 79% 1 yr EFS 89%
Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect
Ahmad Tarhini #ASCO25 @ascocancer.bsky.social
pCR 71% MPR 79% 1 yr EFS 89%
Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect
Ahmad Tarhini #ASCO25 @ascocancer.bsky.social
June 3, 2025 at 4:30 PM
Melanoma orals #6 ➡️ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma
pCR 71% MPR 79% 1 yr EFS 89%
Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect
Ahmad Tarhini #ASCO25 @ascocancer.bsky.social
pCR 71% MPR 79% 1 yr EFS 89%
Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect
Ahmad Tarhini #ASCO25 @ascocancer.bsky.social
Melanoma orals #4 ➡️ ph
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma
D+C with mPR 51.9% with 1 yr EFS 92%
Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma
D+C with mPR 51.9% with 1 yr EFS 92%
Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social
June 3, 2025 at 4:18 PM
Melanoma orals #4 ➡️ ph
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma
D+C with mPR 51.9% with 1 yr EFS 92%
Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social
II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma
D+C with mPR 51.9% with 1 yr EFS 92%
Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social
Melanoma orals #4 ➡️ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma
➡️47.7% pCR
➡️91.7% 12 m RFS for those with MPR
➡️no type 1 DM, AI
Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
➡️47.7% pCR
➡️91.7% 12 m RFS for those with MPR
➡️no type 1 DM, AI
Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
June 3, 2025 at 4:00 PM
Melanoma orals #4 ➡️ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma
➡️47.7% pCR
➡️91.7% 12 m RFS for those with MPR
➡️no type 1 DM, AI
Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
➡️47.7% pCR
➡️91.7% 12 m RFS for those with MPR
➡️no type 1 DM, AI
Tina Heiken @mayocliniccancer.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social
June 3, 2025 at 3:46 PM
Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social
Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25
@ascocancer.bsky.social @aspire-cop.bsky.social
@ascocancer.bsky.social @aspire-cop.bsky.social
June 3, 2025 at 3:32 PM
Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25
@ascocancer.bsky.social @aspire-cop.bsky.social
@ascocancer.bsky.social @aspire-cop.bsky.social
Melanoma orals #3 ➡️ neoadjuvant pembro on stage II/III melanoma
Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high”
Me: Intriguing but hard to understand if true impact given a (moving) historical control
Georgios Karakousis
#ASCO25 @ascocancer.bsky.social
Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high”
Me: Intriguing but hard to understand if true impact given a (moving) historical control
Georgios Karakousis
#ASCO25 @ascocancer.bsky.social
June 3, 2025 at 3:28 PM
Melanoma orals #3 ➡️ neoadjuvant pembro on stage II/III melanoma
Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high”
Me: Intriguing but hard to understand if true impact given a (moving) historical control
Georgios Karakousis
#ASCO25 @ascocancer.bsky.social
Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high”
Me: Intriguing but hard to understand if true impact given a (moving) historical control
Georgios Karakousis
#ASCO25 @ascocancer.bsky.social
Melanoma oral #2 #ASCO25
Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen
@ascocancer.bsky.social
Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen
@ascocancer.bsky.social
June 3, 2025 at 3:20 PM
Melanoma oral #2 #ASCO25
Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen
@ascocancer.bsky.social
Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen
@ascocancer.bsky.social